ML364 |
| Catalog No.GC32720 |
ML364 est un inhibiteur sélectif de la peptidase 2 spécifique de l'ubiquitine (USP2) (IC50 = 1,1 μM) avec une activité anti-proliférative, qui se lie directement À l'USP2 (Kd = 5,2 μM), induit une augmentation de la dégradation de la cycline D1 cellulaire et provoque un arrêt du cycle cellulaire. ML364 augmente les niveaux de ROS mitochondriales et diminue le contenu intracellulaire de l'ATP.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1991986-30-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ML364 is an inhibitor of ubiquitin specific peptidase 2 (USP2), and can be used for the research of breast cancer, extracted from patent WO 2016134026 A1, compound Figure 10G.
[1]. Methods and materials for assessing chemotherapy responsiveness and treating cancer. WO 2016134026 A1
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *